ArticleClinical and translational science2023
Conditional early approval for new drug applications in Japan: Current and emerging issues.
Article in Clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Near-Infrared Fluorescence Probes for Fluorescence-Guided Surgery: Current Clinical Probes and Emerging Candidates.Molecules (Basel, Switzerland) · 2026Review
- Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA.Clinical and translational science · 2026Article
- MT1-MMP-Targeted Photoimmunotherapy via an IR700-Conjugated Bicyclic Peptide.Bioconjugate chemistry · 2026Article
- FDA first to global follow-on: alignment in expedited oncology approvals across EMA, TGA, and PMDA.Frontiers in pharmacology · 2026Article
- The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025Review
- Stem cell therapies for diabetes.Nature medicine · 2025Review
- Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials.International journal of clinical oncology · 2025Article
- Verifying Clinical Benefit of New Anticancer Drugs After Regulatory Approval Based on Exploratory Studies.Therapeutic innovation & regulatory science · 2025Article
- US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines.Investigational new drugs · 2025Article
- Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes.Frontiers in endocrinology · 2025Review
- Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.Clinical and translational science · 2024Article
- Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints.Therapeutic innovation & regulatory science · 2024Article
- Conditional early approval for new drug applications in Japan: Current and emerging issues.Clinical and translational science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.